Health Care/Hospital

So-Young International Inc. Files Its Annual Report on Form 20-F

BEIJING, April 18, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it filed its annual report on Form 20-F for the f...

2025-04-18 19:10 5141

WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site

-          The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors -          Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% -          As the company's largest operational single-use bioreactor...

2025-04-18 14:30 4594

Rhino Rescue Launches New Outdoor Product Lineup to Enhance Safety for Adventurers

LOS ANGELES, April 17, 2025 /PRNewswire/ -- Rhino Rescue, a global leader in emergency preparedness solutions, recently launched its latest innovations: the Rhino Rescue Mini First Aid Kit, a compact yet comprehensive emergency kit specifically designed for high-activity outdoors, the Home First ...

2025-04-17 21:02 2577

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Highlights * Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or64Cu) isotope. * The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capaci...

2025-04-17 21:01 2896

Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025

* CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug CongressUSA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. * The Phase 2 topline results met all primary and secondary endpoints, wit...

2025-04-17 18:34 2687

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases

MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the...

2025-04-17 18:00 2293

Fangzhou Launches Partnership for "AI + Hepatitis Prevention & Control Training Center" at the Greater Bay Area International Liver Disease Forum

GUANGZHOU, China, April 16, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area International Liver Disease Forum to launch the "AI + ...

2025-04-17 09:30 2348

Spring Into Savings: VARON Offers Discounts on Oxygen Solutions for Allergy Season

NEW YORK, April 16, 2025 /PRNewswire/ -- As spring blooms across the country, so does allergy season — a time when pollen, dust, and airborne irritants can aggravate respiratory conditions and make breathing more difficult.VARON , a leading provider of respiratory care solu...

2025-04-17 07:34 1879

Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer

Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT), a medica...

2025-04-17 03:00 2559

Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US

 – Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort – SOMERSET, N.J., April 16, 2025 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced that Medis QFR 3.0, an FDA-cle...

2025-04-17 01:10 2901

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related repor...

2025-04-16 23:22 2656

Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy

SUZHOU, China, April 16, 2025 /PRNewswire/ -- April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval fromChina's National Medi...

2025-04-16 21:00 2146

Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact

* Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain treatments * Recipients include the Children's Hospital of Philadelphia, University of Pennsylvania, King Faisal Specialist Hospital & Research...

2025-04-16 19:36 11395

XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials

SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-deri...

2025-04-15 21:10 2353

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

HIGHLIGHTS * The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of t...

2025-04-15 21:02 2205

Pilatus Biosciences to Present Research on PLT012 at AACR 2025

Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association ...

2025-04-15 20:35 1695

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters:Boston, MA;...

2025-04-15 13:20 2047

Health In Tech Announces First Quarter 2025 Financial Results

* Revenues increased 56% over the first quarter 2024 to $8.0 million, reflecting strong market demand * Income before income taxes more than tripled to $0.7 million, up 257% over the first quarter 2024 * Cash position remained strong at $7.6 million as of March 31, 2025 STUART, Fla., April ...

2025-04-15 04:30 3096

PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company ...

2025-04-14 15:00 2216

MGI Tech Celebrates 10 Years of DNBSEQ™ Technology: Driving Genomics Forward with Speed, Scale, and Accessibility

SHENZHEN, China, April 13, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, proudly marks a decade since the commercialization of its proprietaryDNBSEQ™ sequencing technology

2025-04-14 10:53 2555
1 ... 44454647484950 ... 308

Week's Top Stories